Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancerResearch in context

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancerResearch in context

Summary: Background: Anti-PD-1 and PD-L1 antibodies (mAbs) are approved immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only a minority of patients responds to these treatments and biomarkers predicting response are currently lacking. Methods: Immunoscore-Immun...

Full description

Bibliographic Details
Main Authors: François Ghiringhelli, Frederic Bibeau, Laurent Greillier, Jean-David Fumet, Alis Ilie, Florence Monville, Caroline Laugé, Aurélie Catteau, Isabelle Boquet, Amine Majdi, Erwan Morgand, Youssef Oulkhouir, Nicolas Brandone, Julien Adam, Thomas Sbarrato, Alboukadel Kassambara, Jacques Fieschi, Stéphane Garcia, Anne Laure Lepage, Pascale Tomasini, Jérôme Galon
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:EBioMedicine
Subjects:
Digital pathology
Immunoscore-IC
Prognostic marker
Non-small cell lung cancer
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396423001986

Internet

http://www.sciencedirect.com/science/article/pii/S2352396423001986

Similar Items